Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Scott

Showing results (251-260 of 360) with videos related to

Pageof 36
Sort By:
Mabs|April 1, 2016
Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptorIngrid J G Burvenich, William Farrugia, Fook T Lee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2016
Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895aIngrid J G Burvenich, Sagun Parakh, Hui K Gan, et al.
International Journal of Cancer|April 23, 2009
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNgStefan Bauer, Jeannette C Oosterwijk-Wakka, Nicole Adrian, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2007
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levelsLee M Krug, Daniel T Milton, Achim A Jungbluth, et al.
Nuclear Medicine and Biology|December 14, 2020
Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancerKim H Kwan, Ingrid J G Burvenich, Margaret M Centenera, et al.
Growth Factors (Chur, Switzerland)|August 21, 2013
Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenograftsSze Ting Lee, Hong Ji, David W Greening, et al.
Neuro-Oncology Advances|September 22, 2021
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotinHui K Gan, Sagun Parakh, Andrew B Lassman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
A Phase 1 and Biodistribution Study of ABT-806i, an <sup>111</sup>In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806Hui K Gan, Matthew Burge, Benjamin Solomon, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2015
Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resourcesFrederic H Fahey, Henry Hee-Seong Bom, Arturo Chiti, et al.
Pageof 36

Showing results (251-260 of 360) with videos related to

Sort By:
Pageof 36
Mabs|April 1, 2016
Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptorIngrid J G Burvenich, William Farrugia, Fook T Lee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2016
Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895aIngrid J G Burvenich, Sagun Parakh, Hui K Gan, et al.
International Journal of Cancer|April 23, 2009
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNgStefan Bauer, Jeannette C Oosterwijk-Wakka, Nicole Adrian, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2007
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levelsLee M Krug, Daniel T Milton, Achim A Jungbluth, et al.
Nuclear Medicine and Biology|December 14, 2020
Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancerKim H Kwan, Ingrid J G Burvenich, Margaret M Centenera, et al.
Growth Factors (Chur, Switzerland)|August 21, 2013
Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenograftsSze Ting Lee, Hong Ji, David W Greening, et al.
Neuro-Oncology Advances|September 22, 2021
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotinHui K Gan, Sagun Parakh, Andrew B Lassman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
A Phase 1 and Biodistribution Study of ABT-806i, an <sup>111</sup>In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806Hui K Gan, Matthew Burge, Benjamin Solomon, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2015
Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resourcesFrederic H Fahey, Henry Hee-Seong Bom, Arturo Chiti, et al.
Pageof 36